Public Employees Retirement System of Ohio Increases Stake in Eli Lilly and Co (LLY)

Public Employees Retirement System of Ohio grew its holdings in Eli Lilly and Co (NYSE:LLY) by 0.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 684,533 shares of the company’s stock after buying an additional 2,452 shares during the quarter. Public Employees Retirement System of Ohio owned approximately 0.06% of Eli Lilly and worth $58,555,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Airain ltd acquired a new stake in shares of Eli Lilly and in the second quarter valued at $567,000. Buckingham Asset Management LLC increased its position in Eli Lilly and by 21.3% in the second quarter. Buckingham Asset Management LLC now owns 3,232 shares of the company’s stock worth $266,000 after purchasing an additional 568 shares during the period. BSW Wealth Partners increased its position in Eli Lilly and by 0.6% in the second quarter. BSW Wealth Partners now owns 4,774 shares of the company’s stock worth $393,000 after purchasing an additional 27 shares during the period. Sumitomo Life Insurance Co. increased its position in Eli Lilly and by 4.4% in the second quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock worth $2,675,000 after purchasing an additional 1,370 shares during the period. Finally, Mirador Capital Partners LP increased its position in Eli Lilly and by 5.3% in the second quarter. Mirador Capital Partners LP now owns 12,280 shares of the company’s stock worth $1,011,000 after purchasing an additional 619 shares during the period. Institutional investors own 76.30% of the company’s stock.

A number of brokerages recently commented on LLY. Morgan Stanley set a $86.00 price objective on Eli Lilly and and gave the stock a “hold” rating in a research report on Friday, October 6th. Leerink Swann lifted their price objective on Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, October 24th. Credit Suisse Group lowered Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their price objective for the stock from $84.23 to $88.00 in a research report on Tuesday, October 10th. Finally, Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 price objective (up from $92.00) on shares of Eli Lilly and in a research report on Thursday, October 5th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $92.14.

In other news, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the transaction, the insider now directly owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the transaction, the senior vice president now owns 43,580 shares of the company’s stock, valued at $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold a total of 251,088 shares of company stock valued at $22,041,236 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.

Eli Lilly and Co (NYSE:LLY) opened at $86.57 on Friday. The stock has a market capitalization of $95,320.00, a PE ratio of 41.22, a PEG ratio of 1.60 and a beta of 0.35. Eli Lilly and Co has a 12-month low of $74.00 and a 12-month high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The company’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.88 EPS. equities research analysts predict that Eli Lilly and Co will post 4.22 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be given a dividend of $0.5625 per share. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a dividend yield of 2.60%. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s payout ratio is presently 99.05%.

TRADEMARK VIOLATION WARNING: “Public Employees Retirement System of Ohio Increases Stake in Eli Lilly and Co (LLY)” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://www.com-unik.info/2018/01/06/public-employees-retirement-system-of-ohio-increases-stake-in-eli-lilly-and-co-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

What are top analysts saying about Eli Lilly and? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit